Abstract
In follicular lymphomas with the t(14;18) translocation, there is increased expression of the bcl-2 gene, which is dependent upon regulatory elements within the bcl-2 5′ flanking region and the immunoglobulin heavy-chain gene enhancers. We found that t(14;18) lymphomas expressed C/EBPα, which is not normally expressed in B lymphocytes. Expression of C/EBPα increased bcl-2 expression, and two regions of the bcl-2 P2 promoter that mediated this effect were identified. C/EBPβ was also able to increase bcl-2 promoter activity through these sites. The 5′ site was GC-rich and did not contain a C/EBP consensus sequence; however, C/EBP was observed to interact with this site both in vitro by EMSA and in vivo by chromatin immunoprecipitation assay. The 3′ region contained the Cdx site, which mediates the effect of A-Myb on the bcl-2 promoter. In vivo binding studies revealed that C/EBP interacted with this region of the bcl-2 promoter as well. Decreased expression of C/EBP factors due to targeting of their transcripts by siRNA molecules resulted in downregulation of Bcl-2 protein. We conclude that C/EBPα and C/EBPβ contribute to the deregulated expression of Bcl-2 in t(14;18) lymphoma cells.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Behre G, Singh SM, Liu H, Bortolin LT, Christopeit M, Radomska HS, Rangatia J, Hiddemann W, Friedman AD and Tenen DG . (2002). J. Biol. Chem., 277, 26293–26299.
Boyd KE and Farnham PJ . (1999). Mol. Cell. Biol., 19, 8393–8399.
Burel SA, Harakawa N, Zhou L, Pabst T, Tenen DG and Zhang DE . (2001). Mol. Cell. Biol., 21, 5577–5590.
Chen H-M and Boxer LM . (1995). Mol. Cell. Biol., 15, 3840–3847.
Chen X, Liu W, Ambrosino C, Ruocco MR, Poli V, Romaini L, Quinto I, Barbieri S, Holmes KL, Venuta S and Scala G . (1997). Blood, 90, 156–164.
Christy RJ, Haestner KH, Geiman DE and Lane MD . (1991). Proc. Natl. Acad. Sci. USA, 88, 2593–2597.
Cleary ML, Smith SD and Sklar J . (1986). Cell, 47, 19–28.
Cooper CL, Berrier AL, Roman C and Calame KL . (1994). J. Immunol., 153, 5049–5058.
Dearth LR, Hutt J, Sattler A, Gigliotti A and DeWille J . (2001). J. Cell. Biochem., 82, 357–370.
Graninger WB, Seto M, Boutain B, Goldman P and Korsmeyer SJ . (1987). J. Clin. Inv., 80, 1512–1515.
Heckman C, Mochon E, Arcinas M and Boxer LM . (1997). J. Biol. Chem., 272, 19609–19614.
Heckman CA, Mehew JW and Boxer LM . (2002). Oncogene, 21, 3898–3908.
Heckman CA, Mehew JW, Ying G-G, Introna M, Golay J and Boxer LM . (2000). J. Biol. Chem., 275, 6499–6508.
Hsu W, Kerppola TK, Chen PL, Curran T and Chen-Kiang S . (1994). Mol. Cell. Biol., 14, 268–276.
Ji L, Mochon E, Arcinas M and Boxer LM . (1996). J. Biol. Chem., 271, 22687–22691.
LeClair KP, Blanar MA and Sharp PA . (1992). Proc. Natl. Acad. Sci. USA, 89, 8145–8149.
Legraverend C, Antonson P, Flodby P and Xanthopoulos KG . (1993). Nucl. Acids Res., 21, 1735–1742.
Lekstrom-Himes J and Xanthopoulos KG . (1998). J. Biol. Chem., 273, 28545–28548.
Matsumoto M, Minami M, Takeda K, Sakao Y and Akira S . (1996). FEBS Lett., 395, 143–147.
Oelgeschlager M, Nuchprayoon I, Luscher B and Friedman AD . (1996). Mol. Cell. Biol., 16, 4717–4725.
Ondrey FG, Dong G, Sunwoo J, Chen Z, Wolf JS, Crowl-Bancroft CV, Mukaida N and Van Waes C . (1999). Mol. Carcinogen., 26, 119–129.
Pabst T, Mueller BU, Zhang P, Radomska HS, Narravula S, Schnittger S, Behre G, Hiddemann W and Tenen DG . (2001). Nat. Genet., 27, 263–270.
Poli V . (1998). J. Biol. Chem., 273, 29279–29282.
Ramji DP and Foka P . (2002). Biochem. J., 365, 561–575.
Seto M, Jaeger U, Hockett RD, Graninger W, Bennett S, Goldman P and Korsmeyer SJ . (1988). EMBO J., 7, 123–131.
Tahirov TH, Sato K, Ichikawa-Iwata E, Sasaki M, Inoue-Bungo T, Shiina M, Kimura K, Takata S, Fujikawa A, Morii H, Kumasaka T, Yamamoto M, Ishii S and Ogata K . (2002). Cell, 108, 57–70.
Tenen DG . (2001). Leukemia, 15, 688–689.
Vallejo M, Ron D, Miller CP and Habener JF . (1993). Proc. Natl. Acad. Sci. USA, 90, 4679–4683.
Verbeek W, Gombart AF, Chumakov AM, Muller C, Friedman AD and Koeffler HP . (1999). Blood, 93, 3327–3337.
Wilson BE, Mochon E and Boxer LM . (1996). Mol. Cell. Biol., 16, 5546–5556.
Zhang DE, Zhang P, Wang ND, Hetherington CJ, Darlington GJ and Tenen DG . (1997). Proc. Natl. Acad. Sci. USA, 94, 569–574.
Zhu S, Yoon K, Sterneck E, Johnson PF and Smart RC . (2002). Proc. Natl. Acad. Sci. USA, 99, 207–212.
Acknowledgements
We gratefully acknowledge the assistance of Cathy Crumpton and Lusijah Rott of the Stanford University Digestive Disease Center Flow Cytometry Facility. Dr Gretchen Darlington kindly provided the human C/EBPα cDNA, and Dr Branimir Sikic provided the C/EBPβ expression vector. This work was supported by National Institutes of Health Grant CA56764.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Heckman, C., Wheeler, M. & Boxer, L. Regulation of Bcl-2 expression by C/EBP in t(14;18) lymphoma cells. Oncogene 22, 7891–7899 (2003). https://doi.org/10.1038/sj.onc.1206639
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1206639
Keywords
This article is cited by
-
Functional long-range interactions of the IgH 3′ enhancers with the bcl-2 promoter region in t(14;18) lymphoma cells
Oncogene (2008)
-
The immunoglobulin heavy-chain gene 3′ enhancers deregulate bcl-2 promoter usage in t(14;18) lymphoma cells
Oncogene (2007)
-
WS5, a direct target of oncogenic transcription factor Myc, is related to human melanoma glycoprotein genes and has oncogenic potential
Oncogene (2007)
-
Oct transcription factors mediate t(14;18) lymphoma cell survival by directly regulating bcl-2 expression
Oncogene (2006)